Plain-English translation of NCT07174310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether , a new type of antibody medication, can help people with early-stage Parkinson's disease. The study involves 900 participants who will receive either the medication or a placebo (a dummy treatment) as an intravenous infusion over time. Researchers want to see whether this treatment can slow down how the disease progresses while it's still in its early stages.
Current Parkinson's treatments mainly manage symptoms like tremor and stiffness, but don't slow the underlying disease process. This medication targets a protein believed to drive Parkinson's progression, so this trial is testing whether it might actually slow down the disease itself, especially if started early.
You likely qualify if…
You likely don't qualify if…
If accepted, you will be randomly assigned to receive either or placebo as an intravenous infusion on a regular schedule. You will visit the clinic multiple times to receive your treatment and have your symptoms and overall health monitored. If the initial trial period shows promise, you may be eligible to continue receiving treatment in an open-label extension phase where everyone receives the active medication.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States